Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175


Cervical Spine Involvement is very rare in Patients with Rheumatoid Arthritis Treated actively with Treat to Target Strategy. Ten-Year Results of the NEORACo Study.

Sandström T, Rantalaiho V, Yli-Kerttula T, Kautiainen H, Malmi T, Karjalainen A, Uusitalo T, Julkunen H, Kaipiainen-Seppänen O, Paimela L, Puolakka K, Uutela T, Möttönen T, Hannonen P, Leirisalo-Repo M, Laasonen L, Kauppi M; NEO-RACo Study Group.

J Rheumatol. 2019 Nov 15. pii: jrheum.190139. doi: 10.3899/jrheum.190139. [Epub ahead of print]


Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis.

Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T.

Clin Exp Rheumatol. 2020 Jan-Feb;38(1):99-106. Epub 2019 May 22.


Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.

Rantalaiho V, Sandström T, Koski J, Hannonen P, Möttönen T, Kaipiainen-Seppänen O, Yli-Kerttula T, Kauppi MJ, Uutela T, Malmi T, Julkunen H, Laasonen L, Kautiainen H, Leirisalo-Repo M; NEO-RACo Study Group.

Arthritis Care Res (Hoboken). 2019 Nov;71(11):1450-1458. doi: 10.1002/acr.23782.


Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study.

Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):37-43. Epub 2018 Jun 7.


Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.

Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, Paalanen K, Rannio T, Sokka T.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):55-59. Epub 2018 Jun 7.


Validation of a Finnish version of the Fibromyalgia Impact Questionnaire (Finn-FIQ).

Gauffin J, Hankama T, Kautiainen H, Arkela-Kautiainen M, Hannonen P, Haanpää M.

Scand J Pain. 2012 Jan 1;3(1):15-20. doi: 10.1016/j.sjpain.2011.10.004.


Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group.

PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017.


Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.

Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.

Scand J Rheumatol. 2017 Nov;46(6):425-431. doi: 10.1080/03009742.2016.1266029. Epub 2017 Apr 3.


Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2.


Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases.

Väre P, Nikiphorou E, Hannonen P, Sokka T.

SAGE Open Med. 2016 Jun 14;4:2050312116654404. doi: 10.1177/2050312116654404. eCollection 2016.


Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases.

Nikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T.

BMC Musculoskelet Disord. 2016 Jun 3;17:246. doi: 10.1186/s12891-016-1067-y.


Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up.

Asikainen J, Nikiphorou E, Kaarela K, Lindqvist E, Häkkinen A, Kautiainen H, Hannonen P, Rannio T, Sokka T.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):641-5. Epub 2016 Apr 28.


[What have biological drugs changed in inflammatory rheumatic, skin and bowel diseases?].

Hannonen P, Rantanen T, Jussila A.

Duodecim. 2016;132(4):357-64. Review. Finnish.


Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.

Rannio T, Asikainen J, Kokko A, Hannonen P, Sokka T.

J Rheumatol. 2016 Apr;43(4):699-706. doi: 10.3899/jrheum.141480. Epub 2016 Feb 15.


Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T.

Expert Opin Biol Ther. 2015;15(12):1677-83. doi: 10.1517/14712598.2015.1103733. Epub 2015 Nov 7.


Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.


Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.

Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lähteenmäki J, Uusitalo T, Komulainen R, Möttönen T, Hannonen P.

J Clin Rheumatol. 2015 Jan;21(1):24-30. doi: 10.1097/RHU.0000000000000166.


Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.

Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group.

J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.


Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.


Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.


Do fibromyalgia patients use active pain management strategies? A cohort study.

Gauffin J, Hankama T, Hannonen P, Kautiainen H, Pohjolainen T, Haanpää M.

J Rehabil Med. 2013 May;45(5):477-80. doi: 10.2340/16501977-1133.


Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics.

Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, Soldal DM, Hannonen P.

Clin Exp Rheumatol. 2013 May-Jun;31(3):409-14. Epub 2013 Feb 15.


Neuropathic pain and use of PainDETECT in patients with fibromyalgia: a cohort study.

Gauffin J, Hankama T, Kautiainen H, Hannonen P, Haanpää M.

BMC Neurol. 2013 Feb 14;13:21. doi: 10.1186/1471-2377-13-21.


Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.

Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Möttönen T; FIN-RACo Trial Group.

Ann Rheum Dis. 2013 May;72(5):786-8. doi: 10.1136/annrheumdis-2012-202737. Epub 2013 Jan 24. No abstract available.


Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?

Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T.

Ann Rheum Dis. 2013 May;72(5):745-7. doi: 10.1136/annrheumdis-2012-201943. Epub 2012 Nov 21.


Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.

Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S27-31. Epub 2012 Oct 16.


Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group.

Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647.


Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.


Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.

Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Tarner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JW, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Ostergaard M, Westhovens R, Zochling J, van der Heijde D.

Rheumatology (Oxford). 2012 Aug;51(8):1416-25. doi: 10.1093/rheumatology/kes032. Epub 2012 Mar 24.


Fibromyalgia-worth a diagnosis?

Hannonen P.

Ann Med. 2013 Feb;45(1):1-3. doi: 10.3109/07853890.2011.618810. Epub 2011 Oct 20. No abstract available.


Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.

Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.

Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29.


Sustained improvement of health-related quality of life in patients with early rheumatoid arthritis: a ten-year follow-up study.

Uutela T, Hannonen P, Kautiainen H, Hakala M, Häkkinen A.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1):65-71. Epub 2011 Feb 23.


Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.

Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group.

Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24.


Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.

Karstila KL, Rantalaiho VM, Mustonen JT, Möttönen TT, Hannonen PJ, Leirisalo-Repo M, Kaipiainen-Seppänen OA, Karjalainen AH, Korpela MM; FIN-RACo Trial Group.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1):73-8.


[Rheumatoid arthritis (updated Current Care guideline)].

Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, Möttönen T, Varis T; Suomalaisen Lääkäriseuran Duodecimin ja Suomen Reumatologisen Yhdistyksen Asettama Työryhmä.

Duodecim. 2009;125(19):2131-2. Finnish.


Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84.

Koskinen E, Hannonen P, Sokka T.

J Rheumatol. 2009 Sep;36(9):1873-5. doi: 10.3899/jrheum.090025. Epub 2009 Jul 31.


A mismatch between self-reported physical work load and the HAQ: early identification of rheumatoid arthritis patients at risk for loss of work productivity.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Viikari-Juntura E, Solovieva S, Arkela-Kautiainen M, Leirisalo-Repo M.

Clin Exp Rheumatol. 2009 May-Jun;27(3):422-9.


Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.

Scand J Rheumatol. 2009;38(5):323-7. doi: 10.1080/03009740902946355.


The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.

Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group.

Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447.


[Is diagnosing fibromyalgia necessary?].

Hannonen P.

Duodecim. 2009;125(5):521-6. Finnish.


Positive treatment response improves the health-related quality of life of patients with early rheumatoid arthritis.

Uutela T, Hannonen P, Kautiainen H, Hakala M, Paananen ML, Häkkinen A.

Clin Exp Rheumatol. 2009 Jan-Feb;27(1):108-11.


Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.

Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, Luukkainen R, Vuori K, Blåfield H, Leirisalo-Repo M.

Scand J Rheumatol. 2009 Mar-Apr;38(2):96-103. doi: 10.1080/03009740902756515.


How to assess patients with rheumatoid arthritis and concomitant fibromyalgia?

Mäkinen H, Hannonen P.

J Rheumatol. 2009 Jan;36(1):9-11. doi: 10.3899/jrheum.081100. No abstract available.


Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.

Kauppi MJ, Neva MH, Laiho K, Kautiainen H, Luukkainen R, Karjalainen A, Hannonen PJ, Leirisalo-Repo M, Korpela M, Ilva K, Möttönen T; FIN-RACo Trial Group.

J Rheumatol. 2009 Feb;36(2):273-8. doi: 10.3899/jrheum.080429.


Self-report functioning according to the ICF model in elderly patients with rheumatoid arthritis and in population controls using the multidimensional health assessment questionnaire.

Häkkinen A, Arkela-Kautiainen M, Sokka T, Hannonen P, Kautiainen H.

J Rheumatol. 2009 Feb;36(2):246-53. doi: 10.3899/jrheum.080027.


Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia.

Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B.

Arthritis Rheum. 2008 Nov;58(11):3627-31. doi: 10.1002/art.24037.


Effects of concurrent strength and endurance training on physical fitness and symptoms in postmenopausal women with fibromyalgia: a randomized controlled trial.

Valkeinen H, Alén M, Häkkinen A, Hannonen P, Kukkonen-Harjula K, Häkkinen K.

Arch Phys Med Rehabil. 2008 Sep;89(9):1660-6. doi: 10.1016/j.apmr.2008.01.022.


Stability of the upper neck during isometric neck exercises in rheumatoid arthritis patients with atlantoaxial disorders.

Hakkinen A, Makinen H, Ylinen J, Hannonen P, Sokka T, Neva M, Kautiainen H, Kauppi M.

Scand J Rheumatol. 2008 Sep-Oct;37(5):343-7. doi: 10.1080/03009740802007522.


Strength training and stretching versus stretching only in the treatment of patients with chronic neck pain: a randomized one-year follow-up study.

Häkkinen A, Kautiainen H, Hannonen P, Ylinen J.

Clin Rehabil. 2008 Jul;22(7):592-600. doi: 10.1177/0269215507087486.


Supplemental Content

Loading ...
Support Center